Fluorouracil Tablets

It is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, it can also be incorporated into RNA, inhibiting RNA synthesis by preventing uracil and orotic acid from incorporating into RNA. This product is a cell cycle-specific drug that mainly inhibits S-phase tumor cells.

The main ingredient of this product is: fluorouracil.

This product is white tablets.

It is the main chemotherapy drug for malignant hydatidiform mole and choriocarcinoma. It is also used for adjuvant chemotherapy and palliative treatment of breast cancer, digestive tract tumors (including primary and metastatic liver cancer and pancreatic cancer), ovarian cancer and primary bronchial lung cancer.

The usual dosage for adults is 0.15-0.3g per day, divided into 3-4 doses. The total dosage for a course of treatment is 10-15g.

1. Nausea, loss of appetite or vomiting, usually not serious with most doses, oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea occasionally. Peripheral blood leukopenia is common (mostly reaches the lowest point within 2 to 3 weeks after the start of the course of treatment, and returns to normal after about 3 to 4 weeks), thrombocytopenia is rare. Cough, shortness of breath or cerebellar ataxia are extremely rare; 2. Long-term use can lead to nervous system toxicity; 3. Occasionally myocardial ischemia after medication, angina pectoris and electrocardiogram changes may occur. If confirmed cardiovascular reactions (arrhythmia, angina pectoris, ST segment changes) occur, fluorouracil can no longer be used because of the risk of sudden death.

A very small number of human cases have been diagnosed with congenital malformations due to the use of this drug within the first three months of pregnancy, and this may have long-term effects on the fetus. Therefore, this drug is contraindicated in women within the first three months of pregnancy. Due to the potential mutagenicity, teratogenicity and carcinogenicity of this drug and the possible toxic and side effects in infants, breastfeeding is not allowed during the use of this drug. This drug is contraindicated when accompanied by varicella or herpes zoster. Fluorouracil is contraindicated for use in debilitated patients.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Women are prohibited from using this drug within the first three months of pregnancy. Breastfeeding is prohibited during the use of this product. Precautions for the elderly: Not yet clear.

It has been reported that a variety of drugs can biochemically affect the anti-cancer effect or toxicity of fluorouracil, common drugs include methotrexate, metronidazole and tetrahydrofolate. When used in combination with methotrexate, methotrexate should be given 4 to 6 hours before fluorouracil, otherwise the effect will be reduced. Giving tetrahydrofolate first and then fluorouracil can increase its efficacy. This product can generate neurotoxic metabolites - fluorocitric acid and cause cerebral palsy, so it cannot be injected intrathecally. Allopurinol can reduce the bone marrow suppression caused by fluorouracil. [Dosage instructions] Although oral administration can be absorbed, the peak time of blood drug concentration is longer, and the distribution and concentration of body fluids are not constant, and its bioavailability is not as good as intravenous administration. It is not advisable to drink alcohol or use aspirin drugs at the same time when using this product to reduce the possibility of gastrointestinal bleeding.

Seal tightly and store in a cool, dry place.

50 mg

24 months

Hainan General Alliance Pharmaceutical Co., Ltd.

• Founded in:

  2001-08-30

• Address:

  Yonggui Industrial Zone, Xiuying, Haikou, Hainan

• Tax NO.:

  91460000730054588X

• Registered Funds:

  180 million yuan

• Website:

  Log in to view

• Email:

  Log in to view